Downward Bitch: Irate Yoga Wokes Demand 'Complicit' Instructors Condemn ICE A Sunday yoga class at Minneapolis CorePower Yoga studio turned into an unscripted protest earlier this month, as a group of enraged customers berated front-desk staff for not condemning federal immigration enforcement , prompting the Denver-based chain to ban one regular and agree to post anti-ICE signage in its studios. ...
Downward Bitch: Irate Yoga Wokes Demand 'Complicit' Instructors Condemn ICE A Sunday yoga class at Minneapolis CorePower Yoga studio turned into an unscripted protest earlier this month, as a group of enraged customers berated front-desk staff for not condemning federal immigration enforcement , prompting the Denver-based chain to ban one regular and agree to post anti-ICE signage in its studios. Caught on camera and subsequently gone viral, the confrontation unfolded inside the CorePower studio lobby after a class let out. The video, posted by regular yogi Heather Anderson , 51, shows more than a dozen spandex-clad patrons “spontaneously” demanding answers from two visibly uncomfortable staffers over the company’s stance on Immigration and Customs Enforcement (ICE) . “ Why are you being silent? Let’s hear it - loud and proud, baby! ” Anderson demands, as she films a blonde staffer identified only as “Delaney,” amid approving snaps and cheers from the crowd. Anderson repeatedly presses the staffer for a corporate position on ICE, dismissing the employee’s attempt to “take a pause” as unacceptable. When a second employee tries to speak, the group grows louder, with one student accusing the company of being “complicit” in violent federal immigration actions. This is the raw video of the incident in a CorePower yoga location in Minneapolis, women members throwing a tantrum bc corporate would not denounce ICE. We have a program with white women in this country. The indoctrination and programming runs deep. Note they even snap fingers… pic.twitter.com/yop5I1BzAh — Richard Parker of The Raven's Call (@astheravencalls) February 6, 2026 “You’re not being berated - you’re being asked hard questions,” Anderson snaps, before demanding the return of an anti-ICE sign she says was taken down from the studio’s front door. Throughout the nearly six-minute clip, Lionel Richie’s “All Night Long” blares in the background as the crowd continues its vocal denunciations of the staff, who...
Key Points One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year. 10 stocks we like better than Edgewise Therapeutics › As investors, we should never underestimate the power of a convincing buy recommendation from an analyst. That was the dynamic behind the impressi...
Key Points One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year. 10 stocks we like better than Edgewise Therapeutics › As investors, we should never underestimate the power of a convincing buy recommendation from an analyst. That was the dynamic behind the impressive rise of Edgewise Therapeutics (NASDAQ: EWTX) stock on Monday; after a pundit who's been tracking the biotech for some time reiterated her bullish view on its potential, investors traded it up by 4% on the day. That crushed the 0.5% increase of the bellwether S&P 500 index. A bull stays the course The analyst in question was Piper Sandler's Yasmeen Rahimi. Monday morning, she reiterated her overweight recommendation on Edgewise's equity and her $51 per share price target. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » In fact, according to reports, Rahimi considers Edgewise to be one of Piper Sandler's best stock ideas for this year. This conviction centers around the company's leading cardiovascular drug candidate, EDG-7500, a treatment that targets a genetic heart condition called hypertrophic cardiomyopathy (HCM). The treatment is currently in a Phase 2 clinical trial, with a readout expected in the second quarter of this calendar year. In the analyst's view, its novel functionality sets it apart from HCM treatments currently on the market, which should give it an edge when and if it is approved for commercialization. A muscular development effort That's not the only ace up Edgewise's sleeve, in Rahimi's view. She wrote that several of the company's other pipeline programs have solid potential, and I'd readily agree. In addition to those cardiovascular drugs, the company is also well advanced in developing Sevasemten, a muscular dystrophy treatment...